Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:10:54.826Z.
Calculation as of: 2026-10-06T14:10:54.826Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 533c4696450707580a389d0c8167e09da333cd728c1767827588ef029f48caf5
PEG RATIO
N/A
ArriVent BioPharma, Inc.
Market Cap
$1.33B
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | $1.33B | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.32B | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.34B | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.35B | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A |
| Innovage Holding Corp. (INNV)vs › | $1.22B | N/A |
| Kardigan, Inc. (KARD)vs › | $1.22B | N/A |
| MannKind Corporation (MNKD)vs › | $1.21B | N/A |
| Cronos Group Inc. (CRON)vs › | $1.22B | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
